Corrigendum to Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review

類似資料

• S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure
  著者:: Hui Tang, 等
  出版事項: (2025-09-01)
• Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study
  著者:: Carlos Escriva-Aranda, 等
  出版事項: (2026-06-01)
• Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
  著者:: Ilario Giovanni Rapposelli, 等
  出版事項: (2021-05-01)
• Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
  著者:: Syvart Dennen, 等
  出版事項: (2025-08-01)
• Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
  著者:: Myles A. Ingram, 等
  出版事項: (2022-09-01)